Differentiation and validation of human iPSC-derived atrial cardiomyocytes

Poster Description

There is a growing trend for utilisation of native human cells in drug discovery to overcome common translational disconnects between in vitro screening data, preclinical animal models, and clinical trials in man. Translational assays using cardiomyocytes derived from human induced pluripotent stem cells (hiPSC) are increasingly appreciated as an accessible cell source for cardiac disease modelling, drug screening, and safety pharmacology.

Download
Recommended Publications
Latest Publications
A High-throughput Drug Repurposing Screen of the Potassium Channel, KV3.1, with V434L Mutation (poster)

Manual patch-clamp technique was used to evaluate channel pharmacology using cells transiently transfected with wild-type and V434L mutant channel.

Assessing the variability of hERG data generated using a mock action potential waveform and automated patch clamp platforms

The HESI Cardiac Safety Committee present results from an international ion channel research study that assessed the variability of hERG data generated using automated patch clamp platforms (QPatch 48, Qube 384 and the SyncroPatch 384i) across four different labs.

View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram